Skip to content
10-Q

Quarterly Report

Kite Pharma, Inc.

0001510580-17-000006

← back to feed
Filed
May 8, 2017 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2017 · May 4, 2017 56.55M sh
Capex Q1 2017 · Mar 31, 2017 $2.37M
Capex Q1 2017 · Mar 31, 2016 $9.45M
Cash And Equivalents Q1 2017 · Mar 31, 2017 $565.15M
Cash And Equivalents Q1 2017 · Dec 31, 2016 $114.56M
Cash And Equivalents Q1 2017 · Mar 31, 2016 $199.6M
Cash And Equivalents Q1 2017 · Dec 31, 2015 $392.84M
Stockholders Equity Q1 2017 · Mar 31, 2017 $780.1M
Stockholders Equity Q1 2017 · Dec 31, 2016 $427.97M
Current Liabilities Q1 2017 · Mar 31, 2017 $79.59M
Current Liabilities Q1 2017 · Dec 31, 2016 $55.14M
Total Liabilities Q1 2017 · Mar 31, 2017 $143.65M
Total Liabilities Q1 2017 · Dec 31, 2016 $96.33M
Current Assets Q1 2017 · Mar 31, 2017 $819.23M
Current Assets Q1 2017 · Dec 31, 2016 $427.4M
Total Assets Q1 2017 · Mar 31, 2017 $923.74M
Total Assets Q1 2017 · Dec 31, 2016 $524.3M
Sga Expense Q1 2017 · Mar 31, 2017 $35.84M
Sga Expense restated Q1 2017 · Mar 31, 2016 $16.68M
Rd Expense Q1 2017 · Mar 31, 2017 $65.91M
Rd Expense Q1 2017 · Mar 31, 2016 $34.41M
Net Income Q1 2017 · Mar 31, 2017 −$90.4M
Net Income Q1 2017 · Mar 31, 2016 −$43.92M
Operating Income Q1 2017 · Mar 31, 2017 −$91.91M
Operating Income restated Q1 2017 · Mar 31, 2016 −$45.97M
Revenue Q1 2017 · Mar 31, 2017 $9.84M
Revenue Q1 2017 · Mar 31, 2016 $5.13M